July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
In vitro activity and ocular pharmacokinetics (PK) of SF0166, a topically administered αv integrin antagonist
Author Affiliations & Notes
  • Takeru Furuya
    SciFluor Life Sciences, Cambridge, Massachusetts, United States
  • Ben Askew
    SciFluor Life Sciences, Cambridge, Massachusetts, United States
  • Scott Edwards
    SciFluor Life Sciences, Cambridge, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Takeru Furuya, None; Ben Askew, None; Scott Edwards, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5478. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Takeru Furuya, Ben Askew, Scott Edwards; In vitro activity and ocular pharmacokinetics (PK) of SF0166, a topically administered αv integrin antagonist. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5478.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Small molecule antagonists of αvβ3 and αvβ5 inhibit retinal neovascularization after intraperitoneal or periocular injection. We evaluated the in vitro anti-adhesion and anti-angiogenic activity of SF0166, a small molecule αvβ3 antagonist, as well as ocular PK after topical administration in an ophthalmic solution.

Methods : SF0166 was assessed for binding to αvβ3, αvβ5, αvβ6, and αvβ8 integrins. The ability of SF0166 to block adhesion to vitronectin and fibronectin was tested (L-000845704 positive control). Anti-angiogenic activity was tested in chick chorioallantoic membrane (CAM) assays (staurosporine positive control). Ocular uptake and tissue distribution was assessed after a single topical ocular administration of 5% SF0166 (2.5 mg/eye) to Dutch-Belted rabbits (3 animals [6 eyes]/timepoint).

Results : SF0166 inhibited human integrin-ligand interactions at IC50 values of 0.6 nM for αvβ3, 8 nM for αvβ6, and 13 nM for αvβ8; SF0166 did not inhibit binding to αvβ5. SF0166 was a potent inhibitor of cell adhesion to vitronectin and substantially less potent for fibronectin (Table 1). In the CAM assay, angiogenesis stimulated by bFGF was inhibited in a dose-dependent manner (36% reduction in vessel score at 0.5 μg, 42% at 1 μg, 58% at 4 μg vs 67% for 1 µg staurosporine). Angiogenesis stimulated by VEGF was inhibited in a potent dose-dependent manner (61% at 2 μg; 88% at 5 μg vs 90% for 1 µg staurosporine). Angiogenesis stimulated by PDGF was moderately inhibited with no clear dose response. SF0166 distributed to the choroid and retina after topical ocular administration in amounts that substantially exceeded the cellular IC50 for adhesion to vitronectin; drug concentrations were maintained for >12 hours (Table 2). The concentration of SF0166 in the retina-choroid peaks at 4438 ng/g or 7.8 nmol/g (formula weight of SF0166 is 565 g/mol), or ~8 μM (assuming a tissue density of 1 g/mL).

Conclusions : SF0166 resulted from a drug discovery effort to synthesize small molecule αvβ3 antagonists with physiochemical properties that distribute to the posterior segment of the eye after topical administration in an ophthalmic solution. The high levels of SF0166 in the sclera and low levels in the vitreous show a scleral route of distribution to the back of the eye.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×